申联生物拟以2.37亿元取得世之源控股权

Core Viewpoint - The company, Shenlian Bio, plans to acquire a controlling stake in Yangzhou Shizhiyuan Biotechnology Co., Ltd. for 237 million yuan, aiming to enhance its innovative drug business and establish a dual-main business model of "human pharmaceuticals" and "animal health" [1] Group 1 - Shenlian Bio will use 237 million yuan of its own and self-raised funds, including bank acquisition loans, for the acquisition [1] - The acquisition will be executed through its wholly-owned subsidiary, Shanghai Bentianc Bio-pharmaceutical Co., Ltd. [1] - After the transaction, Bentianc and its concerted parties will hold a total of 51% equity in Shizhiyuan, allowing the company to control 51% of the voting rights [1]